SG11201503946UA - Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease - Google Patents
Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral diseaseInfo
- Publication number
- SG11201503946UA SG11201503946UA SG11201503946UA SG11201503946UA SG11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA
- Authority
- SG
- Singapore
- Prior art keywords
- amelioration
- prevention
- treatment
- viral disease
- pyrimidone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750017P | 2013-01-08 | 2013-01-08 | |
| PCT/EP2014/050165 WO2014108406A1 (fr) | 2013-01-08 | 2014-01-07 | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503946UA true SG11201503946UA (en) | 2015-09-29 |
Family
ID=50070507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503946UA SG11201503946UA (en) | 2013-01-08 | 2014-01-07 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9045486B2 (fr) |
| EP (1) | EP2943495B1 (fr) |
| JP (1) | JP2016518305A (fr) |
| KR (1) | KR20150103285A (fr) |
| CN (1) | CN104918942A (fr) |
| AR (1) | AR094378A1 (fr) |
| AU (1) | AU2014204889A1 (fr) |
| BR (1) | BR112015012693A2 (fr) |
| CA (1) | CA2894642A1 (fr) |
| CL (1) | CL2015001916A1 (fr) |
| CR (1) | CR20150337A (fr) |
| EA (1) | EA201591291A1 (fr) |
| HK (2) | HK1211286A1 (fr) |
| IL (1) | IL239656A0 (fr) |
| MA (1) | MA38323B1 (fr) |
| MX (1) | MX2015008293A (fr) |
| PE (1) | PE20151722A1 (fr) |
| PH (1) | PH12015501517A1 (fr) |
| SG (1) | SG11201503946UA (fr) |
| TW (1) | TW201443053A (fr) |
| WO (1) | WO2014108406A1 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| IL239682B (en) | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| CA2923075C (fr) | 2013-09-12 | 2022-07-26 | Alios Biopharma, Inc. | Composes d'aza-pyridone et leurs utilisations |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| EA036776B1 (ru) | 2015-03-11 | 2020-12-21 | Янссен Байофарма, Инк. | Соединения азапиридона и способы их применения |
| FI3290424T3 (fi) | 2015-04-28 | 2024-02-26 | Shionogi & Co | Substituoituneita polysyklisiä pyridonijohdannaisia ja niiden aihiolääkkeitä |
| KR102409779B1 (ko) | 2015-04-28 | 2022-06-16 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그 |
| US9988390B2 (en) | 2015-10-30 | 2018-06-05 | F. Hoffmann-La Roche Ag | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| RU2745071C2 (ru) | 2015-12-15 | 2021-03-18 | Сионоги Энд Ко., Лтд. | Лекарственный препарат для лечения гриппа, характеризующийся тем, что в нем объединены ингибитор кэп-зависимой эндонуклеазы и лекарственное средство против гриппа |
| WO2017109088A1 (fr) | 2015-12-23 | 2017-06-29 | Savira Pharmaceuticals Gmbh | Dérivés pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale |
| US10858366B2 (en) * | 2016-03-08 | 2020-12-08 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| WO2017158151A1 (fr) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale |
| WO2017158147A1 (fr) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Dérivés de pyrimidone et leur utilisation pour le traitement, la prévention ou l'atténuation des symptômes d'une maladie virale |
| JP6961963B2 (ja) * | 2016-04-01 | 2021-11-05 | 三菱ケミカル株式会社 | フルフラールの製造方法 |
| JP6957518B2 (ja) * | 2016-05-20 | 2021-11-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物 |
| KR102424709B1 (ko) | 2016-05-31 | 2022-07-22 | 칼비스타 파마슈티컬즈 리미티드 | 혈장 칼리크레인 저해제로서 피라졸 유도체 |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| CN110494141A (zh) | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物 |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| HUE057912T2 (hu) | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| MX2020008959A (es) | 2018-02-28 | 2020-10-05 | Novartis Ag | Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h -pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de influenza. |
| EP4010333A1 (fr) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
| EP4126242A1 (fr) * | 2020-03-25 | 2023-02-08 | SRI International | Inhibiteurs tricycliques de l'endonucléase du virus de la grippe |
| EP4074317A1 (fr) | 2021-04-14 | 2022-10-19 | Bayer AG | Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1 |
| WO2024061300A1 (fr) * | 2022-09-22 | 2024-03-28 | Insilico Medicine Ip Limited | Inhibiteurs de trex1 et utilisations associées |
| WO2024083933A1 (fr) | 2022-10-19 | 2024-04-25 | Astrazeneca Ab | 1,3,5-triazines 2,4,6-trisubstituées en tant que modulateurs de cx3cr1 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| WO2005087766A1 (fr) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Inhibiteurs de l'intégrase du vih |
| WO2006030807A1 (fr) | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Dérivé de carbamoylpyridone ayant une activité d'inhibition de la vih intégrase |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| CA2616314A1 (fr) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Composes antiviraux |
| WO2010110231A1 (fr) | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | Dérivé de 3-hydroxy-4-pyridone substitué |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| LT2444400T (lt) | 2009-06-15 | 2018-06-11 | Shionogi & Co., Ltd. | Pakeistasis policiklinis karbamoilpiridono darinys |
| WO2011000566A2 (fr) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Composés et compositions pharmaceutiques pour le traitement de dinfections virales à arn simple brin, sens négatif |
| HUE039859T2 (hu) | 2010-09-24 | 2019-02-28 | Shionogi & Co | Helyettesített policiklusos karbamoil-piridon-származék prodrug |
-
2014
- 2014-01-07 CA CA2894642A patent/CA2894642A1/fr not_active Abandoned
- 2014-01-07 MA MA38323A patent/MA38323B1/fr unknown
- 2014-01-07 KR KR1020157021361A patent/KR20150103285A/ko not_active Application Discontinuation
- 2014-01-07 PE PE2015001253A patent/PE20151722A1/es not_active Application Discontinuation
- 2014-01-07 US US14/149,284 patent/US9045486B2/en not_active Expired - Fee Related
- 2014-01-07 EP EP14703275.9A patent/EP2943495B1/fr not_active Not-in-force
- 2014-01-07 AR ARP140100051A patent/AR094378A1/es unknown
- 2014-01-07 EA EA201591291A patent/EA201591291A1/ru unknown
- 2014-01-07 WO PCT/EP2014/050165 patent/WO2014108406A1/fr active Application Filing
- 2014-01-07 JP JP2015551199A patent/JP2016518305A/ja active Pending
- 2014-01-07 BR BR112015012693A patent/BR112015012693A2/pt active Search and Examination
- 2014-01-07 MX MX2015008293A patent/MX2015008293A/es unknown
- 2014-01-07 SG SG11201503946UA patent/SG11201503946UA/en unknown
- 2014-01-07 CN CN201480004139.1A patent/CN104918942A/zh active Pending
- 2014-01-07 AU AU2014204889A patent/AU2014204889A1/en not_active Abandoned
- 2014-01-08 TW TW103100719A patent/TW201443053A/zh unknown
-
2015
- 2015-06-25 IL IL239656A patent/IL239656A0/en unknown
- 2015-06-25 CR CR20150337A patent/CR20150337A/es unknown
- 2015-07-03 PH PH12015501517A patent/PH12015501517A1/en unknown
- 2015-07-06 CL CL2015001916A patent/CL2015001916A1/es unknown
- 2015-12-08 HK HK15112095.2A patent/HK1211286A1/xx unknown
-
2016
- 2016-01-19 HK HK16100546.1A patent/HK1212686A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014108406A1 (fr) | 2014-07-17 |
| PE20151722A1 (es) | 2015-11-19 |
| PH12015501517A1 (en) | 2015-11-09 |
| AR094378A1 (es) | 2015-07-29 |
| CA2894642A1 (fr) | 2014-07-17 |
| CR20150337A (es) | 2015-11-02 |
| IL239656A0 (en) | 2015-08-31 |
| CN104918942A (zh) | 2015-09-16 |
| MA38323A1 (fr) | 2017-02-28 |
| AU2014204889A1 (en) | 2015-06-11 |
| JP2016518305A (ja) | 2016-06-23 |
| MA38323B1 (fr) | 2018-05-31 |
| US9045486B2 (en) | 2015-06-02 |
| EP2943495B1 (fr) | 2016-12-28 |
| CL2015001916A1 (es) | 2016-01-22 |
| HK1212686A1 (zh) | 2016-06-17 |
| EA201591291A1 (ru) | 2015-12-30 |
| KR20150103285A (ko) | 2015-09-09 |
| US20140194431A1 (en) | 2014-07-10 |
| EP2943495A1 (fr) | 2015-11-18 |
| HK1211286A1 (en) | 2016-05-20 |
| TW201443053A (zh) | 2014-11-16 |
| MX2015008293A (es) | 2016-06-02 |
| BR112015012693A2 (pt) | 2017-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212686A1 (zh) | 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途 | |
| HK1211289A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| IL246564A (en) | 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases | |
| HK1216251A1 (zh) | 吡唑並吡咯烷衍生物及其治病作用 | |
| HK1205128A1 (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease 7-- | |
| HK1212688A1 (zh) | 吡啶酮衍生物及其在治療、改善或預防病毒疾病中的用途 | |
| IL245698B (en) | Purines are converted in positions 2 and 6 and their use for the treatment of tumors | |
| PL3004112T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby | |
| HK1199881A1 (en) | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease -4- | |
| HK1199640A1 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| HK1211288A1 (en) | Naphthyridinone derivatives and their use in the treatment,amelioration or prevention of a viral disease | |
| HRP20182167T1 (hr) | Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba | |
| ZA201600894B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes | |
| AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| HUE047636T2 (hu) | Arginin csontízületi gyulladás kezelésében és/vagy megelõzésében történõ alkalmazásra |